Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02718131 · ClinicalTrials.gov registry record · NA
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)
A NA study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT02718131 is a NA study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.
The verdict
NCT02718131, a NA study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The current study proposes adding BMP-2 (INFUSE), an anabolic agent, at the surgical site of TPA (tibial pseudarthrosis) repair in children with NF1, compared to a control group of patients treated surgically without BMP-2. The following Specific Aims will be addressed: 1) to determine if use of an osteogenic agent (BMP-2) at the time of surgical repair of TPA in NF1 patients will result in improved bone healing; 2) to document safety of BMP-2 in a pediatric NF1 population; and 3) to collect, process, and preserve biologic specimens at the time of surgery for future studies.
Interventions
- PROCEDURE Control Group
- DEVICE INFUSE Bone Graft (BMP-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2020-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02718131
The ClinicalTrials.gov registry entry for NCT02718131 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control Group is the first listed.
NCT02718131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02718131 about?
NCT02718131 is a clinical study titled "A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)". The current study proposes adding BMP-2 (INFUSE), an anabolic agent, at the surgical site of TPA (tibial pseudarthrosis) repair in children with NF1, compared to a control group of patients treated surgically without BMP-2. The following Specific Aims will be addressed: 1) to determine if use of an ...
What is the current status of trial NCT02718131?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2016-03-01. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT02718131?
The interventions under investigation include: Control Group (PROCEDURE), INFUSE Bone Graft (BMP-2) (DEVICE).
Who is sponsoring clinical trial NCT02718131?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.